Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Possibilities of Dapagliflozin-Induced Cardioprotection on Doxorubicin + Cyclophosphamide Mode of Chemotherapy-Induced Cardiomyopathy Publisher Pubmed



Avagimyan A1 ; Sheibani M2, 3 ; Pogosova N4 ; Mkrtchyan L5 ; Yeranosyan H6 ; Aznauryan A7 ; Sahaakyan K8 ; Fogacci F9 ; Cicero A10, 11 ; Shafie D12 ; Sarrafzadegan N13
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Anatomical Pathology and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  2. 2. Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Razi Drug Research Centre, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. National Medical Research Centre of Cardiology named after E. Chazov, Moscow, Russian Federation
  5. 5. Department of Cardiology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  6. 6. Department of Forensic Medicine, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  7. 7. Department of Histology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  8. 8. Head of Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  9. 9. Research Fellow, Atherosclerosis and Metabolic Disorders Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy
  10. 10. Hypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy
  11. 11. Cardiovascular Medicine Unit, Heart, Chest and Vascular Dept, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
  12. 12. Head of Heart Failure Centre, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran
  13. 13. Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: International Journal of Cardiology Published:2023


Abstract

Rationale: The global burden of cardiovascular (CV) and oncological diseases continues to increase. In this regard, the prevention of CV diseases (CVD) before and after cancer treatment is an urgent and unsolved problem in medicine. For this reason, our research group aimed to investigate the possibility of dapagliflozin-related cardioprotection, using an experimental model of chronic Doxorubicin (Adriamycin) + Cyclophosphamide (AC)-mode of chemotherapy-induced cardiomyopathy. Objective: The redox balance, lipid metabolism, endothelial dysfunction, and myocardial damage parameters were measured to evaluate the pathways of dapagliflozin-induced stabilization of CV homeostasis. Methods: For this study, 80 inbred Wistar rats were randomly assigned to four equally sized groups. A model of chronic cardiotoxicity was attained by using doxorubicin and cyclophosphamide co-administration. In the case, the markers of redox-balance, cholesterol metabolism, endothelial dysfunction, myocardial alteration, and morphological examination were assessed. Results: For all parameters, statistically significant deviations were obtained, emphasizing the sequel of AC-mode chemotherapy-related detergent effect on CV system (group 2). Moreover, the data obtained from dapagliflozin-treated groups (group 3) showed that this strategy provide limitation of lipid peroxidation, cholesterol metabolism and endothelial function normalization, with subsequent morphological preservation of myocardium. Conclusion: Dapagliflozin has a broad spectrum of pleiotropic influences, namely cholesterol-lowering, anti-inflammatory, and endothelium-stabilizing properties. These properties provide a favorable environment for the prevention of chemotherapy-related cardiomyopathy. © 2023
Experts (# of related papers)
Other Related Docs
19. Resaerch Paper: Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody, International Journal of Medical Toxicology and Forensic Medicine (2021)